Business Development Leaders
As Business Development Leaders, we believe there is strength in numbers. By sharing knowledge, risks and successes, we can innovate across boundaries and take both of our companies to a new level. We have deep experience in identifying the right opportunities and also have the relationship-building skills to work collaboratively with potential partners.
Doug Giordano, Senior Vice President
Worldwide Business Development
Pfizer's mission is developing breakthrough medicines and bringing them to patients. Our strategy to execute on this mission depends on gathering the best ideas and using the sharpest science that the broader healthcare ecosystem can generate. Our past success has regularly been in partnership with others, and Pfizer is continuing to prioritize business development as core to our strategy. The Worldwide Business Development group supports Pfizer's external opportunities across commercial, development, research and platform technology opportunities. Pfizer's business unit and research unit structure promotes an entrepreneurial spirit, and gives each business unit the power and accountability to make decisions tailored to specific opportunities, in specific markets.
Uwe Schoenbeck, Chief Scientific Officer
External R&D Innovation
Partnerships are increasingly critical to Pfizer's research strategy. Thus Pfizer built External R&D Innovation (ERDI): an externally-focused scientific team of PhDs / MDs embedded within the Pfizer research groups to secure the right external alliances with biopharma and academic partners. ERDI provides a centralized hub for external partners and Pfizer leaders up to clinical POC. ERDI partners closely with Pfizer BD and Legal teams to ensure effective transaction of alliances and deals.
Daniel Karp, Vice President
Business Development, Worldwide Research and Development
In Worldwide Research & Development, we apply a broad portfolio of platform technologies, modalities, and capabilities to the discovery, research, and early development of potential new therapeutics in areas of unmet medical need. Partnerships are critical to innovation within the biopharmaceutical industry, and enable us to work together to advance promising science and bring it closer to patients. As we work on some of the most serious and complex medical challenges, we collaborate closely and creatively with our partners to accelerate and deliver innovation.
Barbara Dalton, Vice President
Pfizer Venture Investments
We invest in innovative emerging companies that have the potential to significantly advance healthcare through product development, technology advancement or service deployment.
Bob Bagdorf, Vice President
Biopharmaceuticals Search & Evaluation
With a dedicated team of business development professionals aligned by therapeutic area, we work closely with our disease area leaders to formulate and execute external opportunity sourcing and assessment strategies to support our businesses in the post-POC (proof-of-concept) space.
Dana Hughes, Vice President
Integration and Alliance Management Team
Using proprietary tools, practices and a cadre of experienced practitioners, we support Pfizer business units, research units - and their partners - with an efficient integration or alliance effort. We work to make deal success more reliable, start-up faster and assure operational stability during a period that might otherwise distract from the core mission - developing breakthrough medicines and bringing them to patients.